A PolyPEPI-SCoV-2 vaccine clinical trial for COVID-2019 infections
Latest Information Update: 28 Oct 2020
At a glance
- Drugs PolyPEPI-SCoV-2 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 19 Oct 2020 According to a PepTC Vaccines Limited media release, Pre-IND regulatory confirmations were obtained from FDA (US), MHRA (UK) and PEI (Germany).
- 22 Jun 2020 New trial record
- 15 Jun 2020 According to a Treos Bio media release, PepTC Vaccines expects to advance to human clinical studies for its investigational PolyPEPI-SCoV-2 vaccine by October 2020. It expects to have preliminary trial results in March 2021.